While 2RTs last trial had mixed results, it is only capable for a narrow band of patients and it needs FDA approval, it is potentially a drain on EYEs very limited resources. Increased sales will increase the demand on cashflow - perhaps the SP will stay low for the next few years until the runs are on the board.Perhaps a suitor could snag a bargain at a discount price if it sees value
EYE Summary (August 2024): Incredibly Undervalued, page-375
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
-0.005(3.33%) |
Mkt cap ! $33.21M | |||
| Open | High | Low | Value | Volume |
| 14.8¢ | 15.0¢ | 14.5¢ | $34.06K | 232.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 329492 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 244742 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |